Advertisement
Australia markets close in 4 hours 29 minutes
  • ALL ORDS

    7,968.80
    -33.70 (-0.42%)
     
  • ASX 200

    7,718.00
    -31.70 (-0.41%)
     
  • AUD/USD

    0.6632
    -0.0006 (-0.08%)
     
  • OIL

    78.15
    -0.47 (-0.60%)
     
  • GOLD

    2,318.50
    +0.50 (+0.02%)
     
  • Bitcoin AUD

    100,336.93
    -2,329.87 (-2.27%)
     
  • CMC Crypto 200

    1,417.03
    +4.07 (+0.29%)
     
  • AUD/EUR

    0.6173
    +0.0000 (+0.00%)
     
  • AUD/NZD

    1.0777
    +0.0024 (+0.23%)
     
  • NZX 50

    11,855.59
    -17.05 (-0.14%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,163.67
    -51.81 (-0.63%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,265.68
    -365.18 (-1.96%)
     
  • Hang Seng

    18,028.07
    -84.56 (-0.47%)
     
  • NIKKEI 225

    38,585.98
    -134.49 (-0.35%)
     

Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series

Inspire Medical Systems
Inspire Medical Systems

MINNEAPOLIS, May 16, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series on Monday, May 22, 2023.

Inspire is scheduled to present at 2:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

ADVERTISEMENT

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443